Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.

被引：0
|
作者：
Ozcan, Muhit
Lee, Seung Tae
Mensah, Felix
Modi, Dipenkumar
Fossa, Alexander
Kim, Won Seog
Paszkiewicz-Kozik, Ewa
Sawalha, Yazeed
Sevindik, Omur Gokmen
Norasetthada, Lalita
Santoro, Armando
Pathiraja, Kumudu
Chakraborty, Samhita
Marinello, Patricia
Lavie, David
机构：
[1] Ankara Univ, Sch Med, Ankara, Turkiye
[2] Univ Maryland Marlene, Baltimore, MD USA
[3] Stewart Green Ebaum Comprehens Canc Ctr, Baltimore, MD USA
[4] Franciscan Hlth, Indiana Blood & & Marrow Transplantat, Indianapolis, IN USA
[5] Karmanos Canc Inst, Detroit, MI USA
[6] Oslo Univ Hosp, Oslo, Norway
[7] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[8] Maria Sklodowska Curie Natl Inst Oncol, Warsaw, Poland
[9] Ohio State Univ, James Canc Hosp & Solove Res Inst, Columbus, OH USA
[10] Istanbul Medipol Univ, Int Sch Med, Istanbul, Turkiye
[11] Chiang Mai Univ, Fac Med, Chiang Mai, Thailand
[12] Humanitas Univ, Pieve & IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Milan, Italy
[13] Merck Co Inc, Rahway, NJ USA
[14] Hadassah Med Ctr, Jerusalem, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7531
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Glofitamab in Patients with relapsed/refractory (R/R) diffuse large B-Cell Lymphoma (DLBCL) and ≥2 prior Lines of Therapy: Key Results of the Phase-II Expansion
    Hutchings, M.
    Dickinson, M.
    Carlo-Stella, C.
    Morschhauser, F.
    Bachy, E.
    Corradini, P.
    Iacoboni, G.
    Khan, C.
    Wrobel, T.
    Offner, F.
    Trneny, M.
    Wu, S. -J.
    Cartron, G.
    Hertzberg, M.
    Sureda, A.
    Perez-Callejo, D.
    Lundberg, L.
    Relf, J.
    Clark, E.
    Humphrey, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 50 - 51
  • [32] A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
    Zhu, Jun
    Song, Yuqin
    Guo, Ye
    Zhou, Keshu
    Li, Wenyu
    Yang, Yu
    Cai, Qingqing
    Wang, Zhao
    Yang, Haiyan
    BLOOD, 2023, 142
  • [33] Glofitamab plus Polatuzumab Vedotin demonstrates durable responses and a manageable safety profile in patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Dietrich, S.
    Hutchings, M.
    Avigdor, A.
    Sureda, A.
    Terol, M. J.
    Bosch, F.
    Corradini, P.
    Larsen, Stauffer T.
    Dominguez, Rueda A.
    Skarbnik, A.
    Jorgensen, J.
    Goldschmidt, N.
    Gurion, R.
    Zinzani, P. L.
    Pinto, A.
    Cordoba, R.
    Bottos, A.
    Huang, Z.
    Simko, S.
    Relf, J.
    de L'Etang, Filezac A.
    Sellam, G.
    Gritti, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 209 - 209
  • [34] Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study
    Herrera, Alex F.
    Matasar, Matthew J.
    Assouline, Sarit
    Kamdar, Manali
    Mehta, Amitkumar
    Fleury, Isabelle
    Kim, Won Seog
    Kim, Tae Min
    Bosch, Francesc
    Radford, John A.
    Bu, Lilian
    Hong, Wan-Jen
    Sehn, Laurie H.
    BLOOD, 2016, 128 (22)
  • [35] Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
    Sehn, Laurie H.
    Hertzberg, Mark
    Opat, Stephen
    Herrera, Alex F.
    Assouline, Sarit
    Flowers, Christopher R.
    Kim, Tae Min
    McMillan, Andrew K.
    Ozcan, Muhit
    Safar, Violaine
    Salles, Gilles
    Hirata, Jamie
    Yang, Annie
    Musick, Lisa
    Matasar, Matthew J.
    BLOOD, 2022, 140 : 9464 - 9467
  • [36] Grading of Neurotoxicity in Patient with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Receiving Tisagenlecleucel Treatment in the JULIET Study
    Maziarz, Richard T.
    Schuster, Stephen J.
    Romanov, Vadim V.
    Rusch, Elisha S.
    Signorovitch, James
    Ericson, Solveig G.
    Maloney, David G.
    Locke, Frederick L.
    BLOOD, 2018, 132
  • [37] Interim evaluation of a targeted radiotherapeutic, CLR 131, in relapsed/refractory diffuse large B-cell lymphoma patients (R/R DLBCL)
    Longcor, J.
    Oliver, K.
    Friend, J.
    Callandar, N.
    ANNALS OF ONCOLOGY, 2019, 30 : 435 - 435
  • [38] Management of Canadian Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World
    Peters, Anthea
    Nowakowski, Grzegorz S.
    Dabas, Rosy
    Amoloja, Theresa
    Xue, Zhenyi
    Koch, Caroline
    Waltl, Eva E.
    Fleury, Isabelle
    BLOOD, 2022, 140 : 3811 - 3813
  • [39] Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Chen, Robert W.
    Ansel, Stephen Maxted
    Zinzani, Pier Luigi
    Vacirca, Jeffrey L.
    Lopez-Guillermo, Armando
    Hutchings, Martin
    Jurczak, Wojciech
    Hess, Georg
    Le Gouill, Steven
    Offner, Fritz
    Santoro, Armando
    Salles, Gilles A.
    Stypinski, Darla
    Laird, Douglas
    Pavlov, Dmitri
    Andreola, Giovanna
    Fly, Kolette D.
    Woolfson, Adrian
    Collins, Graham P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
    Awasthi, Rakesh
    Tam, Constantine S.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Foley, Stephen Ronan
    van Besien, Koen
    Wagner-Johnston, Nina D.
    Kersten, Maria Jose
    Schuster, Stephen J.
    Salles, Gilles
    Maziarz, Richard T.
    Anak, Ozlem
    Pacaud, Lida Bubuteishvili
    Gazi, Lucien
    Waldron, Edward
    Hamilton, Jason
    Pruteanu, Iulian
    Tai, Feng
    Mueller, Karen Thudium
    Waller, Edmund K.
    CANCER RESEARCH, 2018, 78 (13)
12345